No. 24 Illinois stuns Rutgers on Bryant's 40-yard TD reception with 4 seconds left
Contra Costa County adopts gender-neutral pronouns as movement grows in Bay Area
Jones scores 20 in Cent. Conn. St.'s 69-56 win against Holy CrossYourUpdateTV Speaks with Mia Syn, MS, Registered Dietician Nutritionist, about the Many Ways to Give the Gifts of Winter Wellness, Health & Entertaining This Holiday SeasonTrue freshman Luke Kromenhoek threw three touchdown passes and Caziah Holmes ran for two more as host Florida State routed Charleston Southern 41-7 on Saturday afternoon in Tallahassee, Fla. The Seminoles (2-9) convincingly snapped a six-game losing streak and ensured that the Buccaneers (1-11) would finish theirs on a 10-game skid. Florida State has not had much to celebrate during one of its worst seasons in program history. But on Saturday, the Seminoles overcame a rough start and put together one of their more complete efforts of the season. Florida State had not scored more than 21 points in a game prior to Saturday's contest and its 175 rushing yards more than doubled its average (80.5 per game) this season. No single runner had over 40 yards, but seven rushers combined for that output on 34 attempts. The Seminoles entered the game ranked 130th out of 133 FBS teams in rushing offense. Holmes, a senior, finished with three carries for 38 yards, including touchdown runs of 3 and 18 yards. Kromenhoek gave Florida State a sliver of hope for its quarterback future as he completed 13 of 20 passes for 209 yards and no interceptions. He threw TD passes for Amaree Williams, Ja'Khi Douglas and Hykeem Williams. The highlight was a 71-yard touchdown pass to Douglas on the first play from scrimmage of the second half to put the Seminoles ahead 24-0. Douglas finished with 82 yards receiving on three catches, and 10 different Florida State players caught passes for 240 total yards. The Seminoles went 6 of 10 on third downs after averaging only a 25 percent conversion rate all season. Their defense held Charleston Southern to 275 total yards (57 rushing) and forced two turnovers. Florida State was unable to hang on to the shutout, however, as Bucs quarterback Kaleb Jackson found Landon Sauers for a 7-yard touchdown pass with 57 seconds left in the fourth quarter. Jackson completed 22 of 32 passes for 218 yards, one touchdown and one interception. The Bucs defense recorded three sacks led by Davion Williams, who had eight tackles, 2.5 tackles for loss and one sack. The Seminoles will conclude their season next Saturday at home against rival Florida. --Field Level Media
Florida State pounds Charleston Southern for second victory of season
A cacophonous US election has concluded with a historic return to office for Donald Trump. As the Democrats reflect on what might have been, Trump becomes the first US president in almost 130 years to win non-consecutive terms. With the Republican party also securing a majority in the Senate, the scene is set for a more inward-looking America with broader geopolitical and economic consequences for the rest of the globe. Donald Trump will be the next President of the United States. In the end, the election was not as closely contested as anticipated. The US Supreme Court already has a conservative majority, and this may be strengthened further during the second Trump presidency. Trump will potentially be one of the more powerful US presidents in recent memory with the ability to deliver on his ambitious but contested agenda. This includes radical measures on trade, such as his declared intent to put a 60 per cent tariff on all imports from China and an across-the-board 10-20 per cent tariff on imports from other countries. If he goes ahead with these tariffs, expect trade retaliation, most certainly from China. In a highly polarised election, Trump was able to cut through a clutch of swing states, including North Carolina, Georgia and Pennsylvania. Disappointingly for Kamala Harris, she wasn’t able to land a convincing message with the undecided voters. Support from women and the younger demographic turned out to be lower than anticipated. Biden’s poor approval ratings clearly hurt her, and she was unable to set out a differentiated prospectus convincingly. Conversely, Trump was able to rally his base. Other politicians might have been sunk by two impeachments and a convicted felony, but in Trump’s case, it only propelled his supporters with more vigour. Trump’s success was underpinned by his consistency of message. He continued to draw on his original pitch to “Make America Great Again”. This time around, he also promised to “Make America Affordable Again”. He appealed to the “forgotten majority”, workers across the Rust Belt, putting their concerns uppermost in a battle against Washington insiders. The irony of a billionaire putting forward an anti-establishment prospectus continued to be part of the appeal. Trump was consistent in his aim to reduce immigration, advance a protectionist trade policy and realign foreign policy. In an age where politicians are notorious for breaking manifesto commitments, Trump looked to act as he promised. Voters relied on evidence from his first term. Recalling his first term, the electorate was aware that Trump took a hard line on immigration, signed executive orders to support domestic products, left the Trans-Pacific Partnership, withdrew from the Iran nuclear deal, challenged NATO and exited the Paris climate change accord. He outlined an “America First” vision where multilateralism was deemed surplus to requirements. Voters were aware that it was also Trump who dared to be muscular with China. It was also during his earlier presidency that there were overtures to North Korea and an entente achieved between Israel and the United Arab Emirates. That said, it was hard to ignore the manifest coarseness that marked Trump’s initial presidency. His strong-man tendencies had more in common with autocrats such as Putin and Orban than a “leader of the free world”. As allies around the world take stock of this election, they should expect Trump’s second term to be in the same mould. Arguably, he may also advance a more radical agenda to secure his legacy. Trump is likely to expect European allies to pay their fair share of military spending, instead of leaning heavily on America. From a British perspective, the expectation is that Starmer’s administration is likely to emphasise that the “special relationship” between the two nations will endure. However, a Free Trade Agreement still seems somewhat off. In relation to current conflicts, Trump is unlikely to continue funding Ukraine, but it remains to be seen how the underlying tension is resolved. It also remains to be seen if Trump has the appetite to broker a truce in the Middle East. On the trade policy front, a more protectionist approach will impact China but also risks inflationary pressures. Geopolitically, if America looks to retrench, that may have a push-and-pull impact on the balance of power in East Asia. What other signals can we read from Trump’s victory? His substantial achievement lies in converting the Republican party from its country club elitism to a mainstream blue-collar party. The other understated facet of Trumpism is that his message of self-reliance, entrepreneurism and liberty has resonated with minority groups that probably felt too shy to say so publicly. It explains his win in Florida, for example, where the Latino community tilted the balance in his favour. Millions of Americans noted that he oversaw record job creation till the global pandemic came along. On the economy, they took to heart his warning that Harris’ plans for raising taxes would constrain innovation and choke off a recovery. We can say, a victory for Trump signifies the possibility of American exceptionalism as a key organising principle in his second term. Given the current climate of geo-political uncertainty, allies across the globe should take note and recalibrate where necessary. The hope is that Trump can help resolve entrenched conflicts, but the off-setting risk remains an increase in volatility.Florida State pounds Charleston Southern for second victory of seasonLOS ANGELES — Until he sustained a season-ending knee injury last week in the Western Conference final, Galaxy playmaker Riqui Puig was having a tremendous season. So I heard. I watched Puig play only twice this year, once in the Galaxy's season-opening 1-1 draw with Inter Miami and a second time in his team's Fourth of July defeat to LAFC at the Rose Bowl. Outside of short highlight clips on social media, I never saw the former Barcelona prospect, not even when he assisted on the goal that sent the Galaxy to the MLS Cup final. That wasn't a reflection of my interest. Some of my friends will make fun of me for publicly admitting this, but I like Major League Soccer. I covered the league in my first job out of college and have casually kept up with it since. I take my children to a couple of games a year. My 11-year-old son owns Galaxy and LAFC hats but no Dodgers or Lakers merchandise. When flipping through channels in the past, if presented with the choice of, say, college football or MLS, I usually watched MLS. But not this year. While the MLS Cup final between the Galaxy and New York Red Bulls will be shown on Fox and Fox Deportes, the majority of games are now exclusively behind a paywall, courtesy of the league's broadcasting deal with Apple. MLS Season Pass subscriptions were reasonably priced — $79 for the entire season for Apple TV+ subscribers, $99 for non-subscribers — but I was already paying for DirecTV Stream, Netflix, Amazon Prime, PlayStation Plus and who knows what else. MLS became a casualty in my household, as well as in many others, and the possibility of being out of sight and out of mind should be a concern for a league that is looking to expand its audience. Which isn't to say the league made a mistake. This was a gamble MLS had to take. Now in the second year of a 10-year, $2.5 billion deal with Apple, MLS did what Major League Baseball is talking about doing, which is to centralize its broadcasting rights and sell them to a digital platform. Regional sports networks have been decimated by cord cutting, making traditional economic models unsustainable. The move to Apple not only increased the league's broadcast revenues — previous deals with ESPN, Fox and Univision were worth a combined $90 million annually, according to multiple reports — but also introduced a measure of uniformity in the league. The quality of the broadcasts are better than they were under regional sports networks. Viewers know where to watch games and when, as every one of them is on Season Pass and most of them are scheduled to start at 7:30 p.m. local time either on Wednesday or Saturday. "That's been fueling our growth and driving our fan engagement," MLS Commissioner Don Garber said Friday at his annual state of the league address. Apple and MLS declined to reveal the number of League Pass subscribers, but the league provided polling figures that indicated 94% of viewers offered positive or neutral reviews of League Pass. The average viewing time for a game is about 65 minutes for a 90-minute game, according to Garber. In other words, the League Pass is well-liked — by the people who have it. The challenge now is to increase that audience. The launch of League Pass last year coincided with the arrival of Lionel Messi, which presumably resulted in a wave of subscriptions. But the league can't count on the appearance of the next Messi; there is only one of him. MLS pointed to how its fans watch sports on streaming devices or recorded television than any other U.S. sports league, as well as how 71% of its fans are under the age of 45. The league also pointed to how it effectively drew more viewers to the Apple broadcast of Inter Miami's postseason opener with a livestream of a "Messi Cam' on TikTok, indicating further collaborations with wide-reaching entities could be in its future. Garber mentioned how Season Pass is available in other countries. The commissioner also made note of how Apple places games every week in front of its paywall. "What we have, really, is a communication problem," Garber said. "This is new, and we've got to work with Apple, we've got to work with our clubs and we've got to work with our partners to get more exposure to what we think is a great product." The greatest benefit to the league could be Apple's vested interest in improving the on-field product. MLS insiders said Apple has not only encouraged teams to sign more high-profile players but also pushed the league to switch to a fall-to-spring calendar more commonplace in other parts of the world, reasoning that doing so would simplify the process of buying and selling players. The on-field product is what matters. The on-field product is why MLS continues to face competition for viewers from overseas leagues. The on-field product is why the league hasn't succeeded in converting every soccer fan into a MLS fan. And ultimately, if casual viewers such as myself are to pay to watch the Galaxy or LAFC on a screen of some kind, the on-field product will be why. Get local news delivered to your inbox!Q. My husband recently retired from a high-level position. He has things to do but nothing seems to rekindle his spark. I think he is going through a mid-life crisis in later life. Is there such a thing? M.N. What you are describing might be called a late-life crisis . Such a crisis is described by Richard Leider and David Shapiro in their book, “What Do You Want to Be When You Grow Old? The Path of Purposeful Aging” (2021, Berrett-Koehler Publishers, Inc.). Here are some signs the authors identify: experiencing dissatisfaction, a loss of identity, an expectations gap and the feeling that life has peaked. Some also may believe life is a downhill journey. It’s having a feeling of being irrelevant. And it’s not just a guy thing. Both men and women are likely to experience it equally. Several events can cause a crisis in later life. Among them is the death of a loved one, an illness, money problems or no longer being able to walk the usual number of miles or having difficulty with poses in a yoga class. It also could be just boredom, doing the same thing day after day. Then there is retirement , which also can be a cause. For many, the loss of the work role can leave a huge gap in the reason to get up in the morning. For many, work is more than just a paycheck . It can provide a sense of purpose, social connection, structure for the day and knowing someone or some entity expects something from us. In a sense, it’s knowing we are needed. But other causes can cause a crisis in addition to the loss of the work role. For example, being out of touch with current technology, feeling unemployable and invisible in social situations or the marketplace. How do individuals know if they are experiencing a late-life crisis? Here are several questions that can serve as a clue, suggested by Leider and Shapiro. One key to avoiding or managing a late-life crisis is to not go it alone. “Isolation is fatal,” write Lieder and Shapiro. This makes me want to share examples from a recent discussion, not necessarily of a crisis, but increased awareness of the question of “who am I now and who do I want to be?” This discussion took place at a meeting with a group of women who are not going it alone. The group was made up of retired career women who are part of Renewment , a small grassroots movement that supports and inspires career women from work to retirement and beyond. Most were not going through a crisis, yet raised questions that indicated there are issues that may not reach the crisis level, yet still are important. For example, a retired successful entrepreneur asked the question, “Am I doing as much as I am capable of? Do I want to have an impact on a small or large scale?” A recent widow said, “Being a widow is not where I wanted to be at this time in my life; it’s not my identity. I feel so fragmented exploring who I am.” Another added, “I continue to be so hard on myself; always feeling I should do more; I am busy but not happy.” These same women and others in the group shared tips on avoiding problems that could lead to a late-life crisis. A therapist has emerged as an artist in New York and another was deeply involved in the election. A retired professor is traveling to Cuba and a former teacher launched a foundation. They have engagements that reflect a passion and sense of purpose. That’s the topic for next week. A point to remember: No one gets through this life alone. As Leider and Shapiro warn against isolation, remember that finding friends, colleagues, counselors or family members to talk about what’s going on can help avoid a crisis. Stay well everyone and as always, be kind. Helen Dennis is a nationally recognized leader on issues of aging and the new retirement with academic, corporate and nonprofit experience. Contact Helen with your questions and comments at Helendenn@gmail.com . Visit Helen at HelenMdennis.com and follow her on facebook.com/SuccessfulAgingCommunity
Rachel Reeves's tax-raiding budget is 'single greatest threat to food security'
Macron vows to stay in office until 2027Trump asks Supreme Court to delay TikTok ban so he can weigh in after he takes officeDylan Hernández: MLS deal with Apple TV could be hurting league's efforts to grow its fan base
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $North Macedonian political party demands ban on TikTok after at least 17 students injuredNone